ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer
Authors:
- 10 December 2024
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 2110-2111
Abstract
No abstract availableFunding Information
- the Changsha Natural Science Foundation project (kq2007058)
- Beijing Medical Award Foundation-China Endocrine Targeted Therapy Research Fund for Advanced breast cancer (YXJL-2020-0941-0747)
- Scientific Research Project of Hunan Provincial Health Commission (D202302066995)
- the Cutting-edge Cancer Support Treatment Research Project (CPHCF-2023-023)
This publication has 3 references indexed in Scilit:
- Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective TrialsAnnals of Surgical Oncology, 2024
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001